Spherix Global Insights

April 12, 2016

Takeda’s Entyvio Shifts the Treatment Paradigm in Inflammatory Bowel Disease (IBD)

Download Report Overview

Nearly 80% of the gastroenterologists in the study cite recent changes in their IBD patient management, with the majority of biologic use in Moderate to Severe patients. Over 10% recently indicated using biologics earlier than before, over 30% are using more biologics and 20% started patients on Entyvio. 

April 12, 2016 – Zug, Switzerland. For the past several years, biologic treatment options for Crohn’s Disease (CD) and Ulcerative Colitis (UC) have been limited largely to anti-TNF agents. Recently Takeda has introduced Entyvio, an integrin receptor antagonist. A recent study conducted by Spherix Global Insights evaluated the de-identified medical records of 1,032 IBD patients recently switched from one biologic agent to a different brand.

According to Robbie McCarthy, Franchise Head for Gastroenterology at Spherix Global Insights, “The introduction of biologics has changed the face of treatment for patients with moderate-to-severe IBD, and recent biologic switching patterns are predictive of future market shape and brand shares”.

Entyvio, with its unique MOA, is having a very significant impact on current biologic use, turning the approach of sequencing two anti-TNFs on its head.  The impact of this entrant on AbbVie’s Humira and Janssen’s Remicade is significant, resulting in the loss of switch opportunities for both. However, Humira appears better protected against this challenge as a result of being an injectable versus an infusion.  Interestingly, the speed of change in the market is faster than predicted by physicians.  When comparing self-reported feedback with chart audit results brand persistency is reduced by nearly 50%, indicating the increased speed of change we can expect to see in terms of market share.  This is a critical finding for companies projecting market future product performance for inline and pipeline products.

Physicians are eagerly awaiting pipeline products in the form of Xeljanz (Pfizer) and Stelara (Janssen) for UC and CD, respectively. The role of patient preference is strongly highlighted in this report, and the potential interest in Xeljanz as the first oral biologic option for UC sees some very significant predictions for potential market share from the more than 200 physicians who participated in the study.

All company, brand or product names in this document are trademarks of their respective holders.

About Spherix Global Insights
Spherix Global Insights is a newly established business intelligence and market research company. We specialize in renal, autoimmune, neurologic and rare disease markets.  Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.

For more information contact: 
Telephone:  800-661.0571
Email: info@spherixglobalinsights.com